



Genetic mutations and RNAi are standard approaches in biology to study a protein or pathway of interest. Chemical compounds (e.g. inhibitor) with a specific and well-defined effect on a given protein or pathway have many unique advantages, complement other methodologies and help to validate biological targets as "druggable".

However, for many researchers there is no suitable compound available for their protein of interest.

EU-OPENSCREEN is a joint, publically funded European research initiative of compound screening platforms and medicinal chemistry groups at academic universities and public research institutions.

EU-OPENSCREEN develops novel chemical "tool" compounds in collaboration with external scientists from all disciplines of the life sciences.





An EU-OPENSCREEN screening site will take the robust, miniaturised assay together with established orthogonal and counter screens through the high throughput screening process, followed by confirmatory and counter screening.

An EU-OPENSCREEN chemistry partner site will then iteratively improve the hits during the hit-to-tool optimisation process.

CONTACT

EU-OPENSCREEN ERIC

Campus Berlin-Buch

Robert-Rössle-Str. 10

D-13125 Berlin

office@eu-openscreen.eu



www.eu-openscreen.eu